Problems viewing this newsletter? View it in your browser >

Register for our HIV and contraceptives webinar

September 25, 2014

Dear Advocates,

We hope you’re planning to join us on Wednesday, October 1 at 10 AM ET US for the next webinar in our Research & Reality series — Data and Uncertainty: Understanding updates on hormonal contraception and HIV. Charles Morrison of FHI 360, Kristin Wall from Emory University and Mary Lyn Gaffield from WHO will discuss the newest findings and guidance related to contraceptives and HIV risk that were presented at AIDS 2014.

Register here.

There are a range of issues related to hormonal contraception and HIV, but the central question is: what’s the best way to meet women’s needs for effective contraception and HIV prevention? Today, there is uncertainty about whether some methods, such as hormonal injectables like Depo provera, might affect women’s risk of HIV acquisition. This discussion will delve into the uncertainty, recent data and possible next steps for research, programs and policies. 

Much of the data we’ll be discussing were presented or discussed at AIDS 2014 in Melbourne. Whether you attended or not, you probably read reports on this issue from the conference and have questions about what happened — and what it all meant. And this is an especially timely topic, as outlined in a recent editorial from AVAC and some of our partners
This webinar is part of our Research & Reality series, designed to delve into these issues. Check out the full schedule below for links to recordings and slides from earlier webinars and registration links for those upcoming!
UNAIDS, Targets and Civil Society 
In Melbourne, UNAIDS launched a new initiative known as “90-90-90”, which lays out new targets for testing, treatment and virologic suppression. Where did these targets come from, what do they mean—and where does prevention fit in? Chris Collins, Chief of the Community Mobilization Division at UNAIDS, will address these questions and more. 
October 8, 10–11am ET; register here [rescheduled from September 10] 

Results of the iPrEx open-label extension (iPrEx OLE): PrEP uptake, sexual practices and HIV incidence
September 24, 2014; — Animation: Flash, Audio: MP3, Slides: PDF

Latest developments in VMMC research and implementation 
September 17, 2014 — Slides: PDF

State of the Art HIV Cure: Where are we now and where are we going?
September 3, 2014 — Animation: Flash, Audio: MP3, Slides: PDF

As always, questions or comments are most welcome, and we look forward to welcoming you on the webinars!



Diaphragm to prevent unintended pregnancy (and maybe someday HIV)A new contraceptive option, the SILCS Diaphragm, was approved by the FDA for marketing in the US last week and work is underway to get it to women in low-income countries. This development is key as it relates to some of the major research questions under consideration in HIV prevention for women.


Forward This IssueDo you know someone who might be interested in receiving this newsletter?
Forward > 

Unsubscribe You're receiving this because you signed up for our newsletter. Not interested any longer?
Unsubscribe > 

Contact Us T: +1 212 796 6423